Fate Therapeutics (Nasdaq:FATE) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

FATE Stoklara Genel Bakış

Klinik aşamada bir biyofarmasötik şirketi olan Fate Therapeutics, Inc. dünya çapında kanser ve bağışıklık bozuklukları için programlanmış hücresel immünoterapiler geliştirmektedir.

Şirket hakkında

FATE temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	1/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Gelirin yılda 11.71% oranında artması öngörülüyor

Risk Analizi

Önümüzdeki 3 yıl boyunca kazançların yılda ortalama 9.3% oranında düşmesi öngörülüyor

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Hissedarlar geçen yıl sulandırıldı

Son 3 ayda dalgalı hisse senedi fiyatı

Fate Therapeutics, Inc. Rakipler

Organogenesis Holdings

NasdaqCM:ORGO

US$377.8m

Cartesian Therapeutics

NasdaqGM:RNAC

US$429.8m

Anika Therapeutics

NasdaqGS:ANIK

US$370.2m

Emergent BioSolutions

NYSE:EBS

US$496.4m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Fate Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$3.12
52 Haftanın En Yüksek Seviyesi	US$8.83
52 Haftanın En Düşük Seviyesi	US$1.63
Beta	1.84
11 Aylık Değişim	-9.57%
3 Aylık Değişim	-1.58%
1 Yıllık Değişim	77.27%
33 Yıllık Değişim	-94.46%
5 Yıllık Değişim	-77.71%
Halka arzdan bu yana değişim	-52.87%

Son Haberler & Güncellemeler

Industry Analysts Just Made An Incredible Upgrade To Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts

Aug 21

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?

Aug 11

Recent updates

Industry Analysts Just Made An Incredible Upgrade To Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts

Aug 21

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?

Aug 11

Fate Therapeutics: Looking For A Potential Turnaround In 2024

Apr 29

Fate Therapeutics, Inc.'s (NASDAQ:FATE) 28% Dip In Price Shows Sentiment Is Matching Revenues

Apr 23

Fate Therapeutics, Inc. (NASDAQ:FATE) Held Back By Insufficient Growth Even After Shares Climb 57%

Feb 16

Fate Therapeutics Update: A Rally Based On Little Increases Near-Term Risks

Jan 26

Fate Therapeutics, Inc.'s (NASDAQ:FATE) Shares Bounce 30% But Its Business Still Trails The Industry

Dec 19

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Deliver On Growth Plans?

Sep 08

Benign Growth For Fate Therapeutics, Inc. (NASDAQ:FATE) Underpins Its Share Price

Jun 07

Industry Analysts Just Upgraded Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts By 41%

May 08

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?

Apr 17

We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully

Jan 10

Here's Why We're Not Too Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation

Sep 22

Fate Therapeutics: Yes For Speculators, No For Defensive Investors

Aug 30

Needham initiates Fate coverage Therapeutics on potential of stem cell therapies

Jul 28

Hissedar Getirileri

	FATE	US Biotechs	US Pazar
7D	-10.9%	-0.2%	-0.4%
1Y	77.3%	22.1%	34.1%

Getiri vs. Endüstri: FATE geçen yıl % 22.1 oranında getiri sağlayan US Biotechs sektörünü aştı.

Getiri vs Piyasa: FATE geçen yıl % 34.1 oranında getiri sağlayan US Piyasasını aştı.

Fiyat Oynaklığı

Is FATE's price volatile compared to industry and market?
FATE volatility
FATE Average Weekly Movement	12.9%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: FATE hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: FATE 'nin haftalık oynaklığı ( 13% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2007	181	J. Wolchko	www.fatetherapeutics.com

Klinik aşamada bir biyofarmasötik şirketi olan Fate Therapeutics, Inc. dünya çapında kanser ve bağışıklık bozuklukları için programlanmış hücresel immünoterapiler geliştirmektedir. Şirketin kimerik antijen reseptörü (CAR) hedefli NK ve T-hücresi ürün adayları arasında multipl miyelom tedavisi için FT576 ve lenfoma ve otoimmün bozuklukları tedavi etmek için FT522 bulunmaktadır. CAR T-hücre programları arasında hematolojik maligniteleri ve solid tümörleri tedavi etmek için FT819 ve solid tümörleri tedavi etmek için FT825 bulunmaktadır.

Fate Therapeutics, Inc. Temel Bilgiler Özeti

Fate Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
FATE temel i̇stati̇sti̇kler
Piyasa değeri	US$365.55m
Kazançlar(TTM)	-US$175.72m
Gelir(TTM)	US$12.32m

28.8x

P/S Oranı

-2.0x

F/K Oranı

FATE aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
FATE gelir tablosu (TTM)
Gelir	US$12.32m
Gelir Maliyeti	US$121.93m
Brüt Kâr	-US$109.62m
Diğer Giderler	US$66.11m
Kazançlar	-US$175.72m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-1.54
Brüt Marj	-889.96%
Net Kâr Marjı	-1,426.67%
Borç/Özkaynak Oranı	0%

FATE uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

FATE Stoklara Genel Bakış

Ödüller

Risk Analizi

Fate Therapeutics, Inc. Rakipler

NasdaqCM:ORGO

US$377.8m

NasdaqGM:RNAC

US$429.8m

NasdaqGS:ANIK

US$370.2m

NYSE:EBS

US$496.4m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Industry Analysts Just Made An Incredible Upgrade To Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?

Fate Therapeutics, Inc. Appoints Neely Mozaffarian to its Board of Directors

Fate Therapeutics, Inc. Appoints J. Scott Wolchko as Principal Financial and Accounting Officer

Consensus revenue estimates increase by 32%

Price target decreased by 7.7% to US$7.20

Recent updates

Industry Analysts Just Made An Incredible Upgrade To Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?

Fate Therapeutics, Inc. Appoints Neely Mozaffarian to its Board of Directors

Fate Therapeutics, Inc. Appoints J. Scott Wolchko as Principal Financial and Accounting Officer

Consensus revenue estimates increase by 32%

Price target decreased by 7.7% to US$7.20

First quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Fate Therapeutics: Looking For A Potential Turnaround In 2024

Fate Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

Fate Therapeutics, Inc.'s (NASDAQ:FATE) 28% Dip In Price Shows Sentiment Is Matching Revenues

Fate Therapeutics, Inc. Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting

Fate Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $79.999997 million.

Fate Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $79.999997 million.

New minor risk - Shareholder dilution

Fate Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $79.999997 million.

Consensus revenue estimates decrease by 21%, EPS upgraded

Price target increased by 19% to US$7.53

Full year 2023 earnings: EPS exceeds analyst expectations

Fate Therapeutics, Inc. (NASDAQ:FATE) Held Back By Insufficient Growth Even After Shares Climb 57%

Fate Therapeutics, Inc. to Report Q4, 2023 Results on Feb 26, 2024

Fate Therapeutics Update: A Rally Based On Little Increases Near-Term Risks

Founder recently sold US$63k worth of stock

Founder notifies of intention to sell stock

Fate Therapeutics, Inc. Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors

Fate Therapeutics, Inc.'s (NASDAQ:FATE) Shares Bounce 30% But Its Business Still Trails The Industry

Price target decreased by 11% to US$6.50

General Counsel & Corporate Secretary notifies of intention to sell stock

Price target decreased by 8.8% to US$6.63

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Fate Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New minor risk - Share price stability

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Deliver On Growth Plans?

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Fate Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Yu-Waye (Wayne) Chu Intends to Resign as Chief Medical Officer of Fate Therapeutics, Inc. Effective as of July 14, 2023

Benign Growth For Fate Therapeutics, Inc. (NASDAQ:FATE) Underpins Its Share Price

Consensus revenue estimates increase by 36%

Industry Analysts Just Upgraded Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts By 41%

Fate Therapeutics, Inc. Provides Earnings Guidance for the Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?

Consensus revenue estimates increase by 54%, EPS downgraded

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Fate Therapeutics, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Gainey Mckenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Fate Therapeutics, Inc

Founder recently sold US$241k worth of stock

We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully

Now 40% undervalued after recent price drop

Fate Therapeutics, Inc. Expects to Terminate Mark Plavsic as Chief Technical Officer, Effective as of March 6, 2023

Price target decreased to US$59.15

Price target decreased to US$61.10

Fate Therapeutics Announces Clinical Safety and Activity Data of First-Ever iPSC-Derived Car T-Cell Therapy

Insufficient new directors

Price target decreased to US$66.29

Third quarter 2022 earnings released: US$0.86 loss per share (vs US$0.45 loss in 3Q 2021)

Here's Why We're Not Too Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation

Fate Therapeutics: Yes For Speculators, No For Defensive Investors

Chief Financial Officer recently sold US$153k worth of stock

Price target decreased to US$74.05